[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"benign-prostatic-hyperplasia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:benign-prostatic-hyperplasia":26},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,76,0,25,[9,43,72,98,128,148,173,197,222,250,275,290,316,354,376,405,431,457,477,500,519,546,570,593,616],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100480992","bph-global-registry-100480992",false,"NCT05543200","BPH Global Registry","A Global Registry of Treatments and Outcomes for Benign Prostatic Hyperplasia","Inclusion Criteria:\n\n* Primary diagnosis of BPH with LUTS with prescribed medical treatment or surgical intervention\n\nExclusion Criteria:\n\n* Non-symptomatic BPH\n* No treatment prescribed for BPH","MALE","18 Years",{"count":20,"type":21},7500,"ESTIMATED","3 Years","OBSERVATIONAL","Benign prostatic hyperplasia (BPH) is one of the most common performed surgical procedures in urology. Over the past few decades there have been an increasing development of newer surgical treatment options. Additionally, the outcome parameters for BPH treatments have been standardized. While data are available for the initial pivotal studies, post-market release data are lacking. Under the umbrella of uCARE, we have started a prospective, ongoing international registry for recording demographics and outcomes for patients undergoing surgical treatments for BPH.",[26,27],"Benign Prostatic Hyperplasia","Lower Urinary Tract Symptoms",[29],"BPH, Registry, LUTS","RECRUITING","2026-08-11",{"date":33,"type":34},"2026-08-13","ACTUAL",{"date":36,"type":34},"2023-03-13",{"date":38,"type":21},"2028-12",{"name":40,"class":41},"Société Internationale d'Urologie","OTHER",30,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":68,"locationsCount":71},"100555365","sacral-neuromodulation-for-male-overactive-bladder-moab-100555365","NCT06511141","Sacral Neuromodulation for Male Overactive Bladder (MOAB)","Sacral Neuromodulation for Male Overactive Bladder","Key Inclusion Criteria:\n\n1. Participants aged ≥ 18 years at the time of enrollment\n2. Able to complete bladder diaries and patient questionnaires\n3. Primary diagnosis of OAB (urinary urgency incontinence (UUI) or urinary frequency (UF)).\n4. Willing and capable to provide written informed consent and agrees to comply with specified evaluations at clinical investigational sites and attend all follow-up assessments for up to 1 year\n\nKey Exclusion Criteria:\n\n1. Any patient that is not a suitable candidate per investigator discretion\n2. Recent prostate therapy or procedure within the last 6 months at the time of enrollment\n3. Any neurological condition that could interfere with normal bladder function, including stroke, epilepsy, multiple sclerosis, Parkinson's disease, clinically significant peripheral neuropathy, or spinal cord injury (e.g., paraplegia)\n4. Previously implanted with a sacral neuromodulation device, including inactive SNM devices\n5. Any prior treatment with an Implantable Tibial Nerve Stimulation (ITNS)\n6. Positive response to Percutaneous Tibial Nerve Stimulation (PTNS) within the last 3 months at the time of enrollment\n7. Underwent an external trial with any sacral neuromodulation device and was deemed a non-responder by a physician\n8. Any significant medical condition that is likely to interfere with study procedures, device operation, or likely to confound evaluation of study objectives at the discretion of the participating physician.\n9. Uncontrolled diabetes\n10. Known allergic reactions to components of the Axonics SNM System, including titanium, zirconia, polyurethane, epoxy, or silicone",{"count":51,"type":21},150,"INTERVENTIONAL",[54],"NA","To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients.",[57,58,26,59,60,61],"Overactive Bladder","Urinary Urgency Incontinence","Prostate Cancer","Prostatectomy","Urinary Frequency","2026-08-10",{"date":64,"type":34},"2026-08-12",{"date":66,"type":34},"2024-10-22",{"date":38,"type":21},{"name":69,"class":70},"Axonics, Inc.","INDUSTRY",22,{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":12,"sex":17,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":52,"phases":84,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":95,"locationsCount":97},"100650139","vivifi-device-safety-evaluation-for-the-treatment-of-benign-prostatic-hyperplasia-100650139","NCT07745621","Vivifi Device Safety Evaluation for the Treatment of Benign Prostatic Hyperplasia","Safety and Efficacy Evaluation of the Vivifi Device for Treatment of Symptomatic Benign Prostatic Hyperplasia","BPH","Inclusion Criteria:\n\n1. Male 45-80 years of age\n2. Diagnosed with Benign prostatic hyperplasia (BPH)\n3. Prostate volume: ≥ 40 ≤ 100 cc measured by MRI\n4. Qmax ≤ 10 mL\u002Fs on two measures (voided volume ≥ 125 mL)\n5. Assessment of future paternity plans\n6. Signed the study informed consent\n7. Presence of Lower Urinary Tract Symptoms (LUTS) measured by International Prostate Symptoms Score (IPSS) greater than 12\n\nExclusion Criteria:\n\n1. Patients with prior history of relevant scrotal or testicular vascular surgeries or procedures, or vasectomy.\n2. Previous procedural prostate intervention (TURP, laser, ablation, prostate artery embolization, etc.). Prostate biopsies are acceptable\n3. Intravesical prostatic protrusion (IPP) \\> 10 mm\n4. Post-void residual volume (PVR) \\> 200ml\n5. IPSS QoL score ≤ 3\n6. Prostate cancer diagnosis, suspicious DRE, or PSA \\> 10ng\u002FmL\n7. Patients with clinical history of chronic prostatitis.\n8. Patients with clinical history of urinary retention with previous need for catheterization (prior 30 days), or urethral strictures.\n9. Major neurological conditions such as Alzheimer's, Parkinsons, Multiple sclerosis, ALS, spinal cord injury\n10. Patients who are unable to undergo the required anesthesia for the procedure\n11. Patients on testosterone replacement therapy\n12. Patients unable to hold blood thinners, or with coagulation related issues\n13. Patients currently taking medication for BPH (eg. Alpha-blockers or 5-ARIs) who are unwilling or unable to discontinue (washout) prior to treatment (14 days for α-blockers (tamsulosin, alfuzosin, silodosin, doxazosin, terazosin), 8 weeks for finasteride, 5 months for dutasteride)\n14. Diagnosis of Hidradenitis suppurativa","45 Years","80 Years",{"count":83,"type":21},20,[54],"The study objective is to evaluate the safety and feasibility of the Vivifi device to treat symptomatic, benign prostatic hyperplasia (BPH).",[26],[78],"NOT_YET_RECRUITING","2026-07-29",{"date":91,"type":34},"2026-08-04",{"date":93,"type":21},"2026-09",{"date":38,"type":21},{"name":96,"class":70},"Vivifi Medical",1,{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":12,"sex":17,"minAge":105,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":52,"phases":108,"briefSummary":110,"conditions":111,"keywords":117,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":4},"100649929","phase-4-pupil-size-and-choroidal-thickness-changes-with-tamsulosin-vs-silodosin-in-benign-prostatic-hyperplasia-patients-100649929","NCT07743060","Pupil Size and Choroidal Thickness Changes With Tamsulosin vs. Silodosin in Benign Prostatic Hyperplasia Patients","Comparison of Tamsulosin and Silodosin on Pupil Size and Choroidal Thickness in Patients With Benign Prostatic Hyperplasia","Inclusion Criteria:\n\n* Men ≥ 50 years of age with a definitive diagnosis of BPH by a collaborating urologist.\n* Patients with moderate symptoms based onthe International Prostate Symptom Score (IPSS): score 8 to 19\n* No prior use of any alpha-blocker (tamsulosin, silodosin, doxazosin, etc.)\n* Vision adequate for imaging\n* Consent to participate in the study\n* No history of any intraocular surgery; no active or structural ocular disease affecting the pupil\u002Firis, such as glaucoma, uveitis, pseudoexfoliation syndrome, pigment dispersion syndrome.\n* No use of pupil-affecting eye drops within the past 2 weeks\n\nExclusion Criteria:\n\n* High myopia (SE ≤ -6.00 D) or axial length \\> 26.5 mm, in order to control for its effect on choroidal thickness\n* History of trauma or injury to the iris\n* Insufficient image quality during assessments\n* Patient unwilling to continue participation in the study\n* Occurrence of unwanted systemic adverse effects during the study\n* Improper medication adherence during the study\n* Diabetes\n* Hypertension","50 Years",{"count":107,"type":21},40,[109],"PHASE4","Benign prostatic hyperplasia (BPH) is a common disease in men and is treated with alpha-blockers, particularly tamsulosin and silodosin. Studies suggest that these drugs may affect α1a receptors in the iris dilator muscle, causing structural changes in the iris and pupillary disturbances, and increasing the risk of intraoperative floppy iris syndrome (IFIS) during cataract surgery.\n\nMain objective: To compare the effect of tamsulosin and silodosin on pupil size and choroidal thickness in patients with BPH.\n\nMen aged 50 years and older with a definitive diagnosis of BPH who have no prior history of alpha-blocker use will be enrolled in one of the two treatment arms - tamsulosin or silodosin. Assessments will be conducted at two time points - before the start of treatment and after three months of continuous.\n\n* Pupillography will be performed at three standard illumination levels - scotopic 0.04 lux, mesopic 4 lux, and photopic 50 lux - with pupil diameter automatically recorded under each condition using the MS-39 device (manufactured by CSO, Italy).\n* Choroidal assessment will use EDI-OCT (Heidelberg) macular imaging, measuring choroidal thickness at the subfoveal position and at 500 and 1000 micron nasal and temporal points.\n\nTo reduce daily fluctuations related to circadian rhythm, all imaging will be performed within a fixed window of 9-11 a.m. by a single trained operator.\n\ndrug use.",[26,112,113,114,115,116],"Silodosin","Tamsulosin","Choroid","Iris Disease","Tomography, Optical Coherence",[26,112,113,118,119,116],"Choroid\u002Fanatomy & histology","Iris\u002Fanatomy & histology",{"date":121,"type":34},"2026-08-03",{"date":123,"type":21},"2026-08",{"date":125,"type":21},"2027-04",{"name":127,"class":41},"Mohsen Pourazizi",{"id":129,"slug":130,"hasResults":12,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":12,"sex":17,"minAge":105,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":52,"phases":136,"briefSummary":137,"conditions":138,"keywords":141,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":144,"startDateStruct":145,"completionDateStruct":146,"leadSponsor":147,"locationsCount":4},"100649904","phase-4-iris-structural-changes-with-tamsulosin-vs-silodosin-in-benign-prostatic-hyperplasia-patients-100649904","NCT07743034","Iris Structural Changes With Tamsulosin vs. Silodosin in Benign Prostatic Hyperplasia Patients","Comparison of the Efficacy of Tamsulosin and Silodosin on Anatomical Iris Changes in Patients With Benign Prostatic Hyperplasia: A Single-blind Randomized Clinical Trial","Inclusion Criteria:\n\n* Men ≥ 50 years old with a definitive diagnosis of BPH by a urologist colleague.\n* Patients with moderate symptoms based on the International Prostate Symptom Score (IPSS): score 8 to 19\n* No prior use of alpha-blockers (tamsulosin, silodosin, doxazosin, etc.)\n* Satisfactory vision for imaging and acceptable scan quality according to device criteria.\n* Consent to participate in the study\n\nExclusion Criteria:\n\n* Insufficient image quality in assessments\n* History of intraocular surgery\n* Uncontrolled hypertension\n* Iris trauma\n* Patient unwillingness to continue participation in the study\n* Occurrence of unwanted systemic complications during the study\n* Incorrect medication adherence during the study\n* Diabetes\n* Hypertension",{"count":107,"type":21},[109],"Inhibition of alpha-1 adrenergic receptors by drugs such as tamsulosin and silodosin, which are prescribed for the treatment of benign prostatic hyperplasia, can lead to intraoperative floppy iris syndrome (IFIS) during cataract surgery. IFIS is a phenomenon characterized by a small, poorly dilating pupil and causes surgical difficulty.\n\nMain objective: To determine and compare changes in the anatomical structure of the iris in patients with BPH before and after treatment with tamsulosin and silodosin.\n\nMen aged 50 years and older with a definitive diagnosis of BPH who have no prior history of alpha-blocker use will be enrolled in one of the two treatment arms - tamsulosin or silodosin. Imaging will be performed using an MS-39 device (manufactured by CSO, Italy); assessments will be conducted at two time points - before the start of treatment and after three months of continuous drug use. At baseline and three months after treatment, using AS-OCT, the DMR and SMR regions and other ocular angle indices will be measured. Medication adherence will be assessed by counting the capsules used by each patient.\n\nSpecific Objectives:\n\n1. To determine changes in the dilator muscle region (DMR) under scotopic, mesopic, photopic, and post-dilation conditions from baseline to the third month in the tamsulosin \\& silodosin groups and compare them.\n2. To determine changes in SMR under scotopic, mesopic, photopic, and post-dilation conditions from baseline to the third month in the tamsulosin \\& silodosin groups and compare them.",[26,113,112,139,116,140],"Intraoperative Floppy Iris Syndrome","Iris Diseases",[26,113,139,116,142,112,143],"Iris","IFIS",{"date":121,"type":34},{"date":123,"type":21},{"date":125,"type":21},{"name":127,"class":41},{"id":149,"slug":150,"hasResults":12,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":12,"sex":17,"minAge":105,"maxAge":155,"enrollmentInfo":156,"targetDuration":4,"studyType":52,"phases":158,"briefSummary":159,"conditions":160,"keywords":161,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":97},"100649617","early-electroacupuncture-for-post-turp-luts-100649617","NCT07736807","Early Electroacupuncture for Post-TURP LUTS","Early Electroacupuncture Intervention for Lower Urinary Tract Symptoms After Benign Prostatic Hyperplasia Surgery: A Prospective Study","Inclusion Criteria:\n\n1. Patients with benign prostatic hyperplasia (BPH) who have undergone transurethral resection of the prostate (TURP) or holmium laser enucleation of the prostate (HoLEP);\n2. Aged between 50 and 85 years;\n3. Provided signed informed consent.\n\nExclusion Criteria:\n\n1. Pathological examination results confirm the presence of prostatic tumors;\n2. History of lower urinary tract cancers including prostate cancer and bladder cancer within the past 5 years;\n3. Currently receiving or have received treatments based on principles similar to acupuncture within 6 months prior to enrollment, such as electroacupuncture, warm moxibustion, and warm needling moxibustion;\n4. Presence of uncontrolled urinary system infection before surgery (asymptomatic lower urinary tract infection is excluded);\n5. Diagnosed with severe cardiac conditions including severe arrhythmia, severe cardiac insufficiency, acute myocarditis, constrictive pericarditis, pericardial tamponade, severe valvular heart disease, and heart failure;\n6. Confirmed liver injury or potentially severe liver disease (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level \\> 10 times the upper limit of normal);\n7. Confirmed severe renal impairment (estimated glomerular filtration rate (eGFR) \\\u003C 25 mL\u002Fmin\u002F1.73m²), scheduled for or currently undergoing dialysis, or diagnosed with acute contrast-induced nephropathy during screening;\n8. Confirmed severe primary diseases such as dysfunction of other vital organs or diseases of the hematopoietic system;\n9. Confirmed coagulation dysfunction (with definite clinical diagnosis or clear laboratory test results);\n10. Patients with mental illness or cognitive impairment; patients with severe depression, alcohol dependence, or a history of drug abuse;\n11. Patients considered unsuitable for participation in this study by the investigators, or patients with factors strongly associated with study dropout, such as frequently changing working environments that increase the risk of loss to follow-up;\n12. Survival period estimated to be ≤ 6 months by the investigators;\n13. Currently participating in other clinical trials.","85 Years",{"count":157,"type":21},144,[54],"1\\. Project Rationale Benign prostatic hyperplasia (BPH) is one of the most prevalent urological disorders among middle-aged and elderly men, and it represents a common chronic condition in the male population. Its incidence increases from 8% in men aged 31-40 years to over 80% in men aged over 80 years. With the intensification of global population aging, the prevalence of BPH and the corresponding burden on global public healthcare systems have been increasing continuously. BPH not only impairs patients' micturition function and reduces their quality of life, but also may lead to multiple complications involving the urinary system, such as urinary tract infection, bladder calculi and renal function impairment. Although the exact etiology of BPH remains incompletely elucidated, existing studies have confirmed that multiple factors including age, altered hormone levels, genetic background and lifestyle are associated with its pathogenesis.\n\nThe global number of prevalent BPH cases increased from 51 million in 2000 to 94 million in 2019, representing a 70.5% growth in global prevalence during this period. Driven by population aging, changes in lifestyle and the popularization of screening methods such as prostate-specific antigen (PSA) detection, the number of prevalent BPH cases in China increased from 10.2 million in 2000 to 20.3 million in 2019, with a 99.0% growth in prevalence over the period, which exceeds the global average growth rate. Data from the 7th National Population Census of China in 2021 shows that the population aged 60 years and above in China reaches approximately 264 million, accounting for 18.70% of the total population, which is 5.44 percentage points higher than the data from the 6th National Population Census in 2010, and this figure is projected to exceed 400 million by 2050. The intensification of population aging and the corresponding growth in BPH prevalence indicate that BPH has evolved from a common urological disease to a major public health issue that poses a substantial threat to the health of Chinese men.\n\nTransurethral resection of the prostate (TURP) and holmium laser enucleation of the prostate (HoLEP) are routine surgical interventions for BPH, which can effectively reduce prostate volume and improve micturition function in patients. However, persistent lower urinary tract symptoms (LUTS) such as urinary frequency, urgency and dysuria after surgery still negatively affect patients' quality of life. Approximately 30% of patients with pre-operative urological symptoms experience persistent symptoms after surgery. Due to symptom persistence, up to 27% of male patients receive pharmacological intervention for LUTS after TURP. This poses a great challenge to patients' physical and mental health, and effective intervention strategies are urgently needed.\n\nCurrently, the management of post-TURP LUTS mainly relies on conservative interventions such as Pelvic Floor Muscle Training (PFMT) and pharmacological therapy. However, these interventions are typically initiated after urinary catheter removal, which cannot meet the demand for immediate urinary continence after catheter withdrawal. In addition, the therapeutic effect of PFMT requires long-term persistence, which generally leads to poor patient adherence, and the most critical limitation is the lagged intervention timing. Similar issues including delayed intervention and unsatisfactory efficacy also exist in pharmacological therapy. Currently, medications for LUTS secondary to BPH include α-adrenergic receptor blockers, 5-α reductase inhibitors, anticholinergics, β-3 adrenergic receptor agonists and phytotherapy. These agents are routinely used for the management of BPH and BPH-related LUTS, and are widely applied to alleviate persistent or new-onset LUTS after BPH surgery. Although these drugs are generally adopted as standard interventions for post-BPH surgery LUTS, multiple studies have demonstrated that there are no significant differences in objective indicators including symptom score, quality of life index and post-void residual volume between patients receiving these medications after BPH surgery and patients receiving placebo. Currently, there is still a lack of effective and widely accepted intervention regimens for LUTS after BPH surgery.\n\nAgainst the background that existing treatment modalities cannot meet clinical demand, this study proposes early post-operative electroacupuncture as an innovative and scientifically sound intervention strategy. Acupuncture is not merely a simple \"alternative therapy\", but an effective \"non-invasive peripheral neuromodulation technique\" validated by modern medical research. Existing studies have shown that acupuncture exerts a certain therapeutic effect on relieving BPH-related LUTS. For example, in a study conducted by Chen Chao et al., clear conclusions were drawn by comparing the efficacy of acupuncture and α-adrenergic receptor blockers in the treatment of 64 patients with BP",[26],[27,162,163],"Electroacupuncture","TURP","2026-07-25",{"date":166,"type":34},"2026-07-30",{"date":168,"type":21},"2026-07-01",{"date":170,"type":21},"2027-12-01",{"name":172,"class":41},"Zhongda Hospital",{"id":174,"slug":175,"hasResults":12,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":180,"sex":17,"minAge":181,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":52,"phases":184,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":97},"100648617","phase-1-a-clinical-trial-to-evaluate-the-bioequivalence-of-ad-116a-and-ad-1161-under-fed-conditions-in-healthy-adult-male-volunteers-100648617","NCT07722871","A Clinical Trial to Evaluate the Bioequivalence of AD-116A and AD-1161 Under Fed Conditions in Healthy Adult Male Volunteers","An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Bioequivalence of AD-116A Compared to AD-1161 in Healthy Adult Male Volunteers Under Fed Conditions","Inclusion Criteria:\n\n* Body weight equal to or greater than 50 kg and body mass index (BMI) between 18.0 kg\u002Fm2 and 30.0 kg\u002Fm2 at the time of screening visit\n* Age equal to or greater than 19 years in healthy adult male volunteers at the time of screening visit\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational drug within 6 months prior to the scheduled first administration\n* Other exclusions applied",true,"19 Years",{"count":183,"type":21},44,[185],"PHASE1","This study compares and evaluates the bioequivalence of AD-116A and AD-1161 in healthy adult male volunteers under fed conditions.",[26],"2026-07-24",{"date":190,"type":34},"2026-07-27",{"date":192,"type":21},"2026-07",{"date":194,"type":21},"2026-10",{"name":196,"class":70},"Addpharma Inc.",{"id":198,"slug":199,"hasResults":12,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":12,"sex":204,"minAge":80,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":52,"phases":207,"briefSummary":208,"conditions":209,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":218,"leadSponsor":220,"locationsCount":97},"100648623","tamsulosin-monotherapy-versus-combination-therapy-with-tadalafil-25-mg-vs-5-mg-in-managing-male-luts-secondary-to-bph-100648623","NCT07722884","Tamsulosin Monotherapy Versus Combination Therapy With Tadalafil (2.5 mg vs 5 mg) in Managing Male LUTS Secondary to BPH","Safety and Efficacy of Tamsulosin Monotherapy Versus Combination Therapy With Tadalafil (2.5 mg vs 5 mg) in Managing Male LUTS Secondary to BPH","Inclusion Criteria:\n\n* Patients older than 45 years of age.\n* Clinical diagnosis of benign prostatic hyperplasia (BPH) and moderate to severe lower urinary tract symptoms (LUTS) \\[International Prostate Symptom Score (IPSS) ≥ 13\\].\n* Maximum flow rate (Qmax) ≤ 15 mL\u002Fs, prostate volume ≥ 30 mL by transrectal ultrasound.\n\nExclusion Criteria:\n\n* Patients taking α-blockers, beta-blockers, 5-alpha reductase inhibitors, phosphodiesterase-5 (PDE5) inhibitors, anticholinergics, or nitrates were excluded.\n* Patients with a history of prostate or bladder surgery, lower urinary tract procedures, prostate or bladder cancer, neurological conditions affecting bladder function, severe cardiovascular disease, hepatic impairment, diabetes mellitus with complications, kidney dysfunction (acute or chronic), neurogenic bladder, or congenital urinary anomalies.\n* Additionally, patients with recent myocardial infarction, unstable angina, severe heart failure, uncontrolled hypertension, Prostate-Specific Antigen (PSA)\\>4 ng\u002FmL (unless cancer ruled out), active urinary tract infection, urinary retention, and those unavailable for follow-up were also excluded from the study.","ALL",{"count":206,"type":21},90,[54],"This study aims to evaluate the short-term impact and clinical outcomes of tamsulosin monotherapy versus combination therapy with tamsulosin plus tadalafil (2.5 mg vs. 5 mg) on lower urinary tract symptoms (LUTS) severity and patient quality of life in men with benign prostatic hyperplasia (BPH). It also seeks to determine whether the lower tadalafil dose provides adequate symptom relief while minimizing adverse effects over a 12-week follow-up period.",[210,211,113,212,213,27,26],"Safety","Efficacy","Monotherapy","Tadalafil","2026-07-20",{"date":216,"type":34},"2026-07-23",{"date":168,"type":34},{"date":219,"type":21},"2027-01-01",{"name":221,"class":41},"Ain Shams University",{"id":223,"slug":224,"hasResults":12,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":228,"eligibilityCriteria":229,"healthyVolunteers":12,"sex":17,"minAge":230,"maxAge":81,"enrollmentInfo":231,"targetDuration":4,"studyType":52,"phases":233,"briefSummary":234,"conditions":235,"keywords":238,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":247,"leadSponsor":248,"locationsCount":97},"100636760","thulium-laser-enucleation-with-bladder-neck-incision-for-small-volume-benign-prostatic-hyperplasia-100636760","NCT07569874","Thulium Laser Enucleation With Bladder Neck Incision for Small-Volume Benign Prostatic Hyperplasia","Thulium Laser Enucleation of the Prostate Combined With Bladder Neck Incision for Small-Volume Benign Prostatic Hyperplasia: A Multicentre, Randomized, Single-Blind, Four-Arm Controlled Trial","ThuLEP-BNI","Inclusion Criteria:\n\n* Male patients aged 40-80 years.\n* Diagnosis of benign prostatic hyperplasia (BPH) and scheduled to undergo surgical treatment.\n* International Prostate Symptom Score (IPSS) of at least 12, maximum urinary flow rate of no more than 15 mL\u002Fs, with a voided volume greater than 150 mL.\n* Prostate volume of less than 30 mL measured by transrectal ultrasound (TRUS), calculated as length × width × height × 0.52.\n* Ability, as assessed by the investigator, to understand the study requirements and complete the scheduled treatment, follow-up visits, and study-related assessments.\n\nExclusion Criteria:\n\n* Inability or refusal to provide written informed consent, or inability to comply with the required follow-up schedule.\n* Prostate-specific antigen (PSA) level of 10 ng\u002FmL or higher, unless prostate cancer has been excluded by biopsy.\n* Confirmed or suspected prostate or bladder malignancy.\n* Pre-existing bladder neck contracture or urethral stricture before surgery.\n* Known coagulation disorder or abnormal coagulation function.\n* Neurogenic bladder or detrusor underactivity that may affect bladder or urethral sphincter function.\n* Benign prostatic hyperplasia (BPH) complicated by acute urinary tract infection, acute prostatitis, or bacterial prostatitis.\n* History of prostate surgery, urethral stricture, or neurogenic bladder.\n* History of prostate cancer or pelvic radiotherapy.\n* Severe cardiovascular disease, pulmonary disease, or other systemic disease that, in the investigator's judgment, would make the patient unable to tolerate surgery.\n* Participation in another clinical trial related to benign prostatic hyperplasia (BPH) within 3 months before enrolment.\n* Any other condition that, in the investigator's opinion, makes the patient unsuitable for participation in this study.","40 Years",{"count":232,"type":21},932,[54],"This study will evaluate the safety and effectiveness of different surgical treatments for men with small-volume benign prostatic hyperplasia (BPH). Men with small-volume BPH may still have bothersome lower urinary tract symptoms and bladder outlet obstruction, and the best surgical treatment for this group remains uncertain.\n\nIn this multicentre, randomized, single-blind, four-arm controlled trial, 932 eligible men aged 40 to 80 years will be assigned in a 1:1:1:1 ratio to one of four groups: thulium laser enucleation of the prostate combined with bladder neck incision, thulium laser enucleation of the prostate alone, transurethral resection of the prostate (TURP), or transurethral incision of the prostate (TUIP).\n\nThe main goal of the study is to compare the incidence of bladder neck contracture at 6 months after surgery. Secondary outcomes include safety outcomes and changes in urinary symptoms, urinary flow rate, pain score, and symptom response at 3 and 6 months after surgery. Exploratory outcomes include changes in post-void residual urine volume and sexual function scores. Additional exploratory long-term outcomes will also be assessed at 12 months after surgery.",[26,236,237],"Bladder Outlet Obstruction","Lower Urinary Tract Symptoms (LUTS)",[239,240,241,242,27],"Small-Volume Benign Prostatic Hyperplasia","Thulium Laser Enucleation of the Prostate","Bladder Neck Incision","Bladder Neck Contracture","2026-07-18",{"date":245,"type":34},"2026-07-21",{"date":192,"type":21},{"date":38,"type":21},{"name":249,"class":41},"Chinese PLA General Hospital",{"id":251,"slug":252,"hasResults":12,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":12,"sex":17,"minAge":257,"maxAge":258,"enrollmentInfo":259,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":261,"conditions":262,"keywords":264,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":97},"100646035","mri-dti-assessment-of-urethral-internal-sphincter-ring-and-prostate-base-morphology-100646035","NCT07694752","MRI-DTI Assessment of Urethral Internal Sphincter Ring and Prostate Base Morphology","An Observational Study of the Relationship Between the Urethral Internal Sphincter Ring and Prostate Base Morphology Using MRI-DTI Fiber Tracking","Inclusion Criteria:\n\n1. Male participants undergoing clinically indicated pelvic, seminal vesicle, or prostate-related MRI-DTI examination.\n2. Participants with adequate T2-weighted MRI and DTI data for post-processing and quantitative assessment of the bladder neck, prostate base, and proximal urethral region.\n3. Participants in the cross-sectional imaging cohort may include men undergoing MRI for suspected cryptorchidism, suspected seminal vesiculitis, benign prostatic enlargement, or other clinically indicated pelvic or prostate-related evaluations.\n4. Participants in the ADT paired follow-up cohort must have prostate cancer and be scheduled to receive androgen deprivation therapy, with MRI-DTI planned before treatment and during follow-up after ADT.\n5. Participants must be able to comply with MRI examination procedures.\n6. Written informed consent will be obtained when required by the approved study protocol.\n\nExclusion Criteria:\n\n1. Contraindications to MRI, including but not limited to incompatible metallic implants, severe claustrophobia, or other conditions preventing MRI examination.\n2. Known neurogenic bladder dysfunction, including spinal cord injury, multiple sclerosis, Parkinson disease, or other neurological disorders that may significantly affect lower urinary tract function.\n3. History of pelvic radiotherapy.\n4. History of urethral reconstruction, sphincter surgery, or other prior surgery that substantially alters the bladder neck, proximal urethra, or prostate base anatomy.\n5. Severe cardiopulmonary dysfunction, cognitive impairment, psychiatric disorder, or other conditions preventing cooperation with MRI examination or study procedures.\n6. Use of medications or treatments within the previous 3 months that may substantially affect neuromuscular function of the lower urinary tract, as judged by the investigators.\n7. Poor image quality or failed post-processing that prevents reliable visualization or measurement of the urethral internal sphincter ring.","15 Years","90 Years",{"count":260,"type":21},80,"This is a single-center, observational imaging study designed to evaluate the in vivo morphology of the male urethral internal sphincter ring using magnetic resonance diffusion tensor imaging (MRI-DTI) fiber tracking and to investigate its relationship with prostate base morphology.\n\nMale participants undergoing clinically indicated pelvic, seminal vesicle, or prostate-related MRI-DTI examinations will be included. The study population may include patients with benign prostatic enlargement, younger men undergoing MRI for suspected cryptorchidism or suspected seminal vesiculitis, and patients with prostate cancer scheduled to receive androgen deprivation therapy (ADT). All participants will undergo T2-weighted imaging and DTI. T2WI-DTI image registration, dual-region-of-interest fiber tracking, and three-dimensional reconstruction will be used to visualize ring-like muscle fiber structures in the bladder neck, prostate base, and proximal urethral region.\n\nThe cross-sectional imaging cohort will be used to assess the associations between prostate-side morphological parameters, including prostate volume, prostate base diameter or area, and intravesical prostatic protrusion, and sphincter-ring parameters, including ring inner diameter and ring area. The ADT paired cohort will undergo MRI-DTI before treatment and during follow-up after ADT to evaluate whether reduction in prostate volume and prostate base morphology is accompanied by corresponding changes in the urethral internal sphincter ring.\n\nThis study will not alter the participants' existing clinical diagnostic or treatment pathways. Imaging data will be analyzed using standardized post-processing and quantitative measurement procedures. The results may provide in vivo imaging evidence for age- and prostate-related displacement and morphological remodeling of the male urethral internal sphincter and may inform future surgical strategies for identifying, preserving, or reconstructing proximal urinary continence-related structures.",[263,26,59],"Urethral Internal Sphincter Morphology",[265,266,59],"Diffusion Tensor Imaging","Urethral Internal Sphincter","2026-07-17",{"date":214,"type":34},{"date":270,"type":21},"2026-07-15",{"date":272,"type":21},"2028-06-01",{"name":274,"class":41},"Jiangsu Taizhou People's Hospital",{"id":276,"slug":277,"hasResults":12,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":4,"eligibilityCriteria":281,"healthyVolunteers":180,"sex":17,"minAge":181,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":52,"phases":283,"briefSummary":284,"conditions":285,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":286,"startDateStruct":287,"completionDateStruct":288,"leadSponsor":289,"locationsCount":97},"100647948","phase-1-a-clinical-trial-to-evaluate-the-bioequivalence-of-ad-116a-compared-to-ad-1161-in-healthy-adult-male-volunteers-100647948","NCT07715305","A Clinical Trial to Evaluate the Bioequivalence of AD-116A Compared to AD-1161 in Healthy Adult Male Volunteers","An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Bioequivalence of AD-116A Compared to AD-1161 in Healthy Adult Male Volunteers Under Fasting Conditions","Inclusion Criteria:\n\n* Body weight equal to or greater than 50kg and Body mass index (BMI) between 18.0 kg\u002Fm2 and 30.0 kg\u002Fm2 at the time of screening visit\n* The Age equal to or greater than 19 in healthy adult male volunteers at the time of screening visit\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration\n* Other exclusions applied",{"count":183,"type":21},[185],"The study compare and evaluate the bioequivalence between the administration of AD-116A and the administration of AD-1161 in healthy adult male volunteers",[26],{"date":214,"type":34},{"date":192,"type":21},{"date":123,"type":21},{"name":196,"class":70},{"id":291,"slug":292,"hasResults":12,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":4,"eligibilityCriteria":296,"healthyVolunteers":12,"sex":17,"minAge":181,"maxAge":4,"enrollmentInfo":297,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":299,"conditions":300,"keywords":301,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":4},"100637278","a-study-to-track-the-safety-of-vesomni-in-men-in-south-korea-treated-in-routine-clinical-practice-for-the-urinary-symptoms-of-benign-prostatic-hyperplasia-enlarged-prostate-100637278","NCT07619105","A Study to Track the Safety of Vesomni in Men in South Korea Treated in Routine Clinical Practice for the Urinary Symptoms of Benign Prostatic Hyperplasia (Enlarged Prostate)","Post-marketing Observational Study for Vesomni Modified Release Tablet 6 mg\u002F0.4 mg (Solifenacin Succinate\u002FTamsulosin Hydrochloride) in Male Patients With Moderate to Severe Storage Symptoms and Voiding Symptoms Associated With BPH Who Are Not Adequately Responding to Treatment With Tamsulosin Monotherapy in South Korea","Inclusion Criteria:\n\n* A patient (adult male) who receives treatment with Vesomni, according to the approved local label during the registration period.\n\nExclusion Criteria:\n\n* A patient with any contraindication for Vesomni, according to the approved local label.\n* A patient who enrolled or is planning to enroll in any study of an investigational medicine during the observation period.",{"count":298,"type":21},600,"Benign prostatic hyperplasia (BPH), also known as an enlarged prostate, happens more often in men as they age. This condition causes a sudden need to pass urine, which is hard to control. Men with an enlarged prostate may need to pass urine many times during the day and night which can affect their wellbeing. There are treatments available, like tamsulosin but they don't work well in some men and can cause further health problems. Vesomni is approved in South Korea to treat urinary symptoms in men with an enlarged prostate, when treatment with tamsulosin doesn't work well enough.\n\nThis study will track the safety of Vesomni given to men in South Korea who have moderate to severe symptoms from an enlarged prostate, who have previously been treated with tamsulosin and found it didn't work well. The safety of Vesomni is tracked by mainly collecting information from their medical records. The sponsor will ask for extra information to be collected, and if any health problems were caused by Vesomni. In this study, researchers want to learn about the safety of Vesomni and how well it controls symptoms in men with an enlarged prostate.\n\nThe men's own doctor decides on treatment, as part of routine clinical practice, not the sponsor (Astellas). This study is about collecting information only. Most information about the safety and control of symptoms will be collected from medical records. The sponsor will also ask for extra information to be collected. All information will be collected for up to 24 weeks after the men start treatment with Vesomni.",[26],[302,303,304,305,306,307],"Pollakiuria","Micturition urgency","Voiding Symptoms","Vesomni","Solifenacin succinate","Tamsulosin hydrochloride",{"date":309,"type":34},"2026-07-16",{"date":311,"type":21},"2026-09-30",{"date":313,"type":21},"2030-11-30",{"name":315,"class":70},"Astellas Pharma Korea, Inc.",{"id":317,"slug":318,"hasResults":12,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":322,"eligibilityCriteria":323,"healthyVolunteers":12,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":324,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":326,"conditions":327,"keywords":332,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":353},"100645777","selective-median-lobe-surgery-outcomes-study-100645777","NCT07699718","Selective Median Lobe Surgery Outcomes Study","UNVEIL-BPO Median Lobe Study: An International Multicenter Evaluation of Selective Median Lobe Resection and Enucleation","UNVEIL-BPO","Inclusion Criteria:\n\n* Male patients aged 45 years or older.\n\n  * Moderate-to-severe lower urinary tract symptoms due to benign prostatic obstruction or urinary retention requiring transurethral surgery.\n  * Preoperative findings suggesting median lobe-dominant or median lobe-related obstruction.\n  * Planned selective median lobe-only TURP, HoLEP, or anatomical endoscopic enucleation as part of routine clinical care.\n  * Available baseline International Prostate Symptom Score, uroflowmetry and\u002For postvoid residual volume, prostate volume, intravesical prostatic protrusion measurement, and cystoscopic assessment.\n  * Ability to provide written informed consent and comply with the follow-up schedule.\n\nExclusion Criteria:\n\n* Previous prostate surgery for benign prostatic hyperplasia.\n* Known urethral stricture requiring treatment before or during the index procedure.\n* Known neurogenic lower urinary tract dysfunction.\n* Active prostate cancer or bladder cancer requiring treatment that may confound urinary outcomes.\n* Planned complete TURP, complete HoLEP\u002FAEEP, or lateral lobe-dominant surgery.\n* Severe kissing lateral lobe obstruction considered to require complete surgery rather than selective median lobe surgery.\n* Inability to provide valid baseline or follow-up outcome data.",{"count":325,"type":21},420,"This prospective multicenter observational cohort study will evaluate clinical outcomes after selective median lobe transurethral surgery for benign prostatic obstruction. Eligible men with lower urinary tract symptoms or urinary retention who are scheduled for selective median lobe-only TURP, HoLEP, or anatomical endoscopic enucleation as part of routine clinical care will be enrolled and followed after surgery.\n\nThe study will collect preoperative clinical data, symptom scores, uroflowmetry, postvoid residual volume, prostate volume, intravesical prostatic protrusion measurements, cystoscopic anatomical findings, intraoperative variables, and postoperative outcomes. The primary outcome is composite clinical failure at 12 months.\n\nThe main aim is to identify practical preoperative urology-based anatomical and functional predictors of clinical failure after selective median lobe surgery and to develop an exploratory prediction model that may help improve patient selection in future practice.",[26,328,329,330,331],"Lower Urinary Tract Symptoms (LUTS) in Men With Benign Prostatic Hyperplasia (BPH)","Benign Prostatic Obstruction","Urinary Retention","Median Lobe Prostatic Enlargement",[333,334,335,336,337,163,338,339,340,341,342,343],"Median lobe","Intravesical prostatic protrusion","Selective median lobe surgery","Selective median lobe enucleation","Selective median lobe resection","HoLEP","Anatomical endoscopic enucleation of the prostate","Uroflowmetry","Postvoid residual","Clinical failure","Ejaculation preservation","2026-07-09",{"date":346,"type":34},"2026-07-13",{"date":348,"type":21},"2026-09-01",{"date":350,"type":21},"2030-12-01",{"name":352,"class":41},"Necmettin Erbakan University",2,{"id":355,"slug":356,"hasResults":12,"nctId":357,"briefTitle":358,"officialTitle":358,"acronym":359,"eligibilityCriteria":360,"healthyVolunteers":12,"sex":17,"minAge":105,"maxAge":4,"enrollmentInfo":361,"targetDuration":4,"studyType":52,"phases":363,"briefSummary":364,"conditions":365,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":375},"100540121","safety-and-effectiveness-of-the-optilume-bph-catheter-system-in-a-post-market-study-100540121","NCT06312722","Safety and Effectiveness of the Optilume® BPH Catheter System in a Post-Market Study","PEAK","Inclusion Criteria:\n\n1. Male subject ≥ 50 years old\n2. Diagnosed with lower urinary tract symptoms (LUTS) secondary to obstructive benign prostatic hyperplasia (BPH)\n3. Able to be treated with the Optilume BPH Catheter System in accordance with the Instructions for Use\n4. Prostate volume \\\u003C 80 g with a prostatic urethral length between 32-55 mm as determined by trans-rectal ultrasound (TRUS)\n5. International Prostate Symptom Score (IPSS) ≥ 13\n6. Peak urinary flow rate (Qmax) 5-15 mL\u002Fsec with minimum voided volume of 125 mL\n7. Willing to provide informed consent and comply with protocol required follow-up\n\nExclusion Criteria:\n\n1. Unwilling to abstain from sexual intercourse or use a condom for 30 days post-procedure and utilize a highly effective contraceptive for at least 12 months post-procedure\n2. Presence of an artificial urinary sphincter, penile prosthesis, or stent(s) in the urethra or prostate\n3. Any prior minimally invasive intervention (e.g., TUNA, Balloon, Microwave, Rezūm, UroLift) or surgical intervention of the prostate\n4. Confirmed or suspected malignancy of prostate or bladder. Negative prostate biopsy required within 6 months of enrollment if PSA at baseline is \\> 4 ng\u002FmL with free PSA \\\u003C 25%.\n5. Active urinary tract infection (UTI) confirmed by culture\n6. Neurogenic bladder or sphincter abnormalities or neurological disorders that might affect bladder or sphincter function\n7. History of overt urinary incontinence requiring the use of pads\n8. Previous or current diagnosis of urethral strictures, bladder neck contracture or detrusor muscle spasms\n9. Current post-void residual volume (PVR) \\> 300 mL or catheter dependent bladder drainage\n10. Known poor detrusor muscle function (e.g., Qmax \\\u003C 5 mL\u002Fsec)\n11. Active bladder, ureteral, or urethral stones or stone passage within the last 3 months\n12. Current poorly controlled diabetes (i.e., hemoglobin A1c ≥ 8%)\n13. Anatomy (e.g., presence of false passage or size of meatus) is not suitable for treatment with the Optilume BPH Catheter System\n14. Obstructive median lobe in the opinion of the investigator",{"count":362,"type":21},92,[54],"The goal of this clinical trial is to verify the continued safety and effectiveness for the Optilume BPH Catheter System.",[26],"2026-07-08",{"date":368,"type":34},"2026-07-10",{"date":370,"type":34},"2024-02-07",{"date":372,"type":21},"2031-02-07",{"name":374,"class":70},"Urotronic Inc.",7,{"id":377,"slug":378,"hasResults":12,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":382,"eligibilityCriteria":383,"healthyVolunteers":12,"sex":17,"minAge":105,"maxAge":4,"enrollmentInfo":384,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":385,"conditions":386,"keywords":387,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":97},"100644381","preoperative-anxiety-and-surgical-fear-in-holmium-laser-enucleation-of-the-prostate-and-transurethral-resection-of-the-prostate-patients-with-benign-prostatic-hyperplasia-100644381","NCT07663097","Preoperative Anxiety and Surgical Fear in Holmium Laser Enucleation of the Prostate and Transurethral Resection of the Prostate Patients With Benign Prostatic Hyperplasia","Evaluation of the Effects of Preoperative Anxiety and Surgical Fear on Postoperative Functional Outcomes and Patient Satisfaction in Patients Scheduled for HoLEP and TURP Due to Benign Prostatic Hyperplasia: A Prospective Observational Study","HoLEP and TURP","Inclusion Criteria:\n\n* Male patients aged 50 years or older\n* Diagnosis of benign prostatic hyperplasia (BPH)\n* Scheduled to undergo HoLEP or TURP\n* Ability to understand and complete study questionnaires\n* Provided written informed consent\n\nExclusion Criteria:\n\n* History of severe psychiatric disorder\n* Active psychiatric treatment\n* Neurogenic bladder or neurologic voiding dysfunction\n* Diagnosis of prostate cancer\n* Previous prostate surgery\n* Inability to comply with study procedures or follow-up visits",{"count":260,"type":21},"Benign prostatic hyperplasia (BPH) is a common condition in older men and may cause bothersome lower urinary tract symptoms that can negatively affect quality of life. Surgical treatment with Holmium Laser Enucleation of the Prostate (HoLEP) or Transurethral Resection of the Prostate (TURP) is often recommended when medical therapy is insufficient.\n\nThis prospective observational study aims to evaluate whether preoperative anxiety, depression, and surgical fear influence postoperative functional outcomes, urinary continence, erectile function, and patient satisfaction in patients undergoing HoLEP or TURP for BPH. Participants will complete validated psychological and functional questionnaires before surgery and during postoperative follow-up visits at 1 and 3 months. The study will also assess changes in psychological status after surgery and compare outcomes between HoLEP and TURP patients.\n\nThe findings may help improve preoperative patient counseling and identify patients who could benefit from additional psychological support before surgery.",[26],[78,388,163,389,390,391,392,393,394,395],"HOLEP","Preoperative anxiety","surgical fear","depression","Patient satisfaction","lower urinary tract symptoms","urinary incontinence","erectile function","2026-06-23",{"date":398,"type":34},"2026-06-26",{"date":400,"type":21},"2026-06-14",{"date":402,"type":21},"2027-06-08",{"name":404,"class":41},"Hitit University",{"id":406,"slug":407,"hasResults":12,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":4,"eligibilityCriteria":411,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":412,"targetDuration":4,"studyType":52,"phases":413,"briefSummary":414,"conditions":415,"keywords":418,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":424,"startDateStruct":426,"completionDateStruct":428,"leadSponsor":430,"locationsCount":353},"100642494","spinal-versus-general-anesthesia-in-open-simple-prostatectomy-100642494","NCT07643415","Spinal Versus General Anesthesia in Open Simple Prostatectomy","Effect of Spinal Versus General Anesthesia on Postoperative Bleeding in Patients Undergoing Open Simple Prostatectomy: A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Male patients aged 18 years or older.\n* Diagnosis of benign prostatic hyperplasia (BPH).\n* Scheduled to undergo open simple prostatectomy.\n* American Society of Anesthesiologists (ASA) physical status I-III.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Refusal or inability to provide informed consent.\n* Patients scheduled for radical prostatectomy due to prostate cancer.\n* Emergency surgery.\n* Known coagulation disorders or clinically significant thrombocytopenia.\n* Ongoing anticoagulant or antiplatelet therapy that cannot be discontinued according to institutional protocols.\n* Contraindication to spinal anesthesia.\n* Participation in another interventional clinical trial that may affect study outcomes.\n* Administration of tranexamic acid or any additional hemostatic agent during the perioperative period.",{"count":260,"type":21},[54],"Open simple prostatectomy is still performed for selected patients with benign prostatic hyperplasia, particularly in cases with large prostate volume. Postoperative bleeding, hematuria, clot retention, and transfusion requirement are clinically important complications after this procedure.\n\nThis prospective randomized controlled trial will compare the effects of spinal anesthesia and general anesthesia on postoperative bleeding in patients undergoing open simple prostatectomy. Participants will be randomized into two groups: spinal anesthesia or general anesthesia. Tranexamic acid or any additional hemostatic agent will not be used. Postoperative bleeding will be assessed using hemoglobin and hematocrit changes, transfusion requirement, hematuria, clot retention, need for bladder irrigation, and bleeding-related reintervention.\n\nThe study aims to determine whether spinal anesthesia is associated with reduced postoperative bleeding compared with general anesthesia in open simple prostatectomy.",[416,26,417],"Urologic Neoplasms","Anesthesia",[419,420,421,422],"Open simple prostatectomy","Spinal anesthesia","general anesthesia","postoperative bleeding","2026-06-15",{"date":425,"type":34},"2026-06-16",{"date":427,"type":34},"2026-04-29",{"date":429,"type":21},"2026-09-15",{"name":404,"class":41},{"id":432,"slug":433,"hasResults":12,"nctId":434,"briefTitle":435,"officialTitle":436,"acronym":437,"eligibilityCriteria":438,"healthyVolunteers":12,"sex":17,"minAge":105,"maxAge":4,"enrollmentInfo":439,"targetDuration":4,"studyType":52,"phases":441,"briefSummary":442,"conditions":443,"keywords":445,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":455,"locationsCount":97},"100641769","phase-4-tamsulosin-with-or-without-tadalafil-for-trial-without-catheter-after-acute-urinary-retention-due-to-benign-prostatic-hyperplasia-100641769","NCT07654413","Tamsulosin With or Without Tadalafil for Trial Without Catheter After Acute Urinary Retention Due to Benign Prostatic Hyperplasia","Tamsulosin With Versus Without Tadalafil for Trial Without Catheter After Acute Urinary Retention Due to Benign Prostatic Hyperplasia: A Prospective Double-Blind Randomized Trial","TAMS-TAD-TWOC","Inclusion Criteria:\n\n* Male patient aged 50 years or older.\n* First episode of spontaneous painful acute urinary retention.\n* Successful urethral catheterization at presentation.\n* Drained urine volume at presentation of at least 300 mL.\n* Clinical impression of benign prostatic obstruction or benign prostatic hyperplasia based on history, digital rectal examination, and\u002For ultrasound evidence of enlarged prostate.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Previous episode of acute urinary retention.\n* Chronic painless urinary retention phenotype.\n* Active urinary tract infection or sepsis.\n* Gross hematuria with clot retention.\n* Suspected or known urethral stricture.\n* Neurogenic bladder or major neurologic disease affecting voiding.\n* History of prostate cancer or bladder cancer.\n* Previous prostate surgery.\n* Current use of nitrates or guanylate cyclase stimulators.\n* Contraindication to tadalafil or tamsulosin.\n* Severe hypotension or unstable cardiovascular disease.\n* Severe renal impairment.\n* Severe hepatic impairment.\n* Current or recent use of phosphodiesterase type 5 inhibitors before enrollment.",{"count":440,"type":21},320,[109],"Acute urinary retention is a common emergency in men with benign prostatic hyperplasia. After bladder drainage with a urethral catheter, patients usually undergo a trial without catheter to determine whether they can pass urine again without recatheterization.\n\nThis study will evaluate whether adding tadalafil 5 mg once daily to tamsulosin 0.4 mg once daily improves the chance of successful trial without catheter in men with first-episode acute urinary retention due to presumed benign prostatic hyperplasia.\n\nParticipants will be randomly assigned to receive either tamsulosin plus tadalafil or tamsulosin plus a matching placebo. Study medication will start within 24 hours after catheterization. The catheter will be removed on Day 7. If the first trial without catheter fails, the catheter will be reinserted and a second rescue trial without catheter will be performed on Day 14.\n\nThe main outcome is overall catheter-free success by Day 14. Participants will also be followed for recurrent urinary retention, post-void residual urine, urinary flow, catheter-related complications, drug-related adverse events, and the need for benign prostatic hyperplasia-related surgery within 3 months.",[444,26,329],"Acute Urinary Retention",[446,447,113,213,26],"Trial Without Catheter","TWOC","2026-06-12",{"date":450,"type":34},"2026-06-17",{"date":452,"type":34},"2026-06-08",{"date":454,"type":21},"2027-12",{"name":456,"class":41},"Beni-Suef University",{"id":458,"slug":459,"hasResults":12,"nctId":460,"briefTitle":461,"officialTitle":462,"acronym":4,"eligibilityCriteria":463,"healthyVolunteers":12,"sex":17,"minAge":105,"maxAge":4,"enrollmentInfo":464,"targetDuration":4,"studyType":52,"phases":466,"briefSummary":467,"conditions":468,"keywords":469,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":473,"completionDateStruct":474,"leadSponsor":476,"locationsCount":97},"100642454","phase-4-tamsulosin-dose-escalation-or-silodosin-switch-before-trial-without-catheter-in-bph-related-acute-urinary-retention-100642454","NCT07650968","Tamsulosin Dose Escalation or Silodosin Switch Before Trial Without Catheter in BPH-Related Acute Urinary Retention","Tamsulosin 0.4 mg Continuation Versus Dose Escalation to 0.8 mg Versus Switch to Silodosin 8 mg for Trial Without Catheter After Acute Urinary Retention Due to Benign Prostatic Hyperplasia: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Male patients aged 50 years or older.\n* Acute urinary retention requiring urethral catheterization.\n* Presumed acute urinary retention secondary to benign prostatic enlargement or benign prostatic obstruction.\n* Already receiving tamsulosin 0.4 mg once daily for at least 4 weeks before the acute urinary retention episode.\n* Successful urethral catheterization at presentation.\n* Initial catheterized urine volume ≤1000 mL, with a clinical presentation consistent with painful acute urinary retention.\n* Prostate enlargement on ultrasound or clinical assessment consistent with benign prostatic hyperplasia or benign prostatic obstruction.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Known or suspected prostate cancer.\n* Previous prostate surgery.\n* Previous urethral stricture disease or urethral surgery.\n* Neurogenic bladder or known neurological disease affecting voiding.\n* Chronic urinary retention rather than acute painful retention.\n* Acute urinary retention due to non-BPH causes, including clot retention, bladder stone obstruction, acute prostatitis, urethral trauma, or drug-induced retention.\n* Severe urinary tract infection, sepsis, or fever at presentation.\n* Gross hematuria requiring irrigation.\n* Failed urethral catheterization or need for suprapubic catheterization.\n* Current use of silodosin, alfuzosin, doxazosin, terazosin, tadalafil, anticholinergics, beta-3 agonists, or other drugs that may significantly affect voiding.\n* Severe renal impairment requiring urgent intervention.\n* Symptomatic postural hypotension or recurrent syncope.\n* Known hypersensitivity to silodosin.\n* Severe hepatic impairment.\n* Inability to comply with follow-up.",{"count":465,"type":21},378,[109],"This randomized controlled trial will compare three medication strategies before trial without catheter in men with acute urinary retention due to benign prostatic hyperplasia who were already taking tamsulosin 0.4 mg once daily before the retention episode. After urethral catheterization, eligible participants will be randomly assigned to one of three groups for 7 days: continuation of tamsulosin 0.4 mg once daily, escalation to tamsulosin 0.8 mg once daily, or switching to silodosin 8 mg once daily. The urethral catheter will be removed on Day 7, and the ability to void successfully without re-catheterization will be assessed. Follow-up will continue to Day 30, with additional recording of catheter-free status, recurrent urinary retention, urinary flow, post-void residual urine, symptom scores, adverse drug events, catheter-related complications, and the need for later benign prostatic hyperplasia-related surgery.",[444,26],[446,113,112,470],"Catheter-free status","2026-06-11",{"date":425,"type":34},{"date":452,"type":34},{"date":475,"type":21},"2027-06",{"name":456,"class":41},{"id":478,"slug":479,"hasResults":12,"nctId":480,"briefTitle":481,"officialTitle":482,"acronym":483,"eligibilityCriteria":484,"healthyVolunteers":12,"sex":17,"minAge":105,"maxAge":4,"enrollmentInfo":485,"targetDuration":4,"studyType":52,"phases":487,"briefSummary":488,"conditions":489,"keywords":491,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":496,"startDateStruct":497,"completionDateStruct":498,"leadSponsor":499,"locationsCount":97},"100642693","water-vapor-thermal-therapy-versus-ejaculation-sparing-bipolar-transurethral-enucleation-for-benign-prostatic-hyperplasia-100642693","NCT07648888","Water Vapor Thermal Therapy Versus Ejaculation-Sparing Bipolar Transurethral Enucleation for Benign Prostatic Hyperplasia","Water Vapor Thermal Therapy Versus Ejaculation-Sparing Bipolar Transurethral Enucleation of the Prostate for Benign Prostatic Hyperplasia: A Prospective Comparative Study","REZ-ESBTUEP","Inclusion Criteria:\n\n* Male patients aged 50 years or older.\n* Symptomatic benign prostatic hyperplasia with moderate-to-severe lower urinary tract symptoms.\n* International Prostate Symptom Score (IPSS) 13 or higher.\n* Prostate volume 30 to 80 mL measured by transrectal ultrasound.\n* Maximum urinary flow rate (Qmax) 15 mL\u002Fs or less with voided volume 150 mL or more.\n* Post-void residual urine volume 250 mL or less.\n* Failed, intolerant, or unwilling to continue medical therapy for benign prostatic hyperplasia.\n* Sexually active within the previous 3 months.\n* Preserved antegrade ejaculation at baseline.\n* Patient wishes to preserve ejaculation.\n* Ability to complete the International Prostate Symptom Score (IPSS), International Index of Erectile Function-5 (IIEF-5), and Male Sexual Health Questionnaire-Ejaculatory Dysfunction Short Form (MSHQ-EjD-SF).\n* Written informed consent.\n\nExclusion Criteria:\n\n* Suspected or confirmed prostate cancer.\n* Abnormal prostate-specific antigen or digital rectal examination suspicious for malignancy unless prostate cancer has been excluded according to standard clinical practice.\n* Previous prostate surgery.\n* Previous urethral surgery likely to affect instrumentation or study outcomes.\n* Urethral stricture disease.\n* Neurogenic bladder dysfunction.\n* Active urinary tract infection until adequately treated.\n* Bladder stones requiring concomitant surgery.\n* Prostate volume less than 30 mL or more than 80 mL.\n* Baseline anejaculation or severe ejaculatory dysfunction.\n* No sexual activity during the previous 3 months.\n* Chronic indwelling urethral or suprapubic catheter.\n* Recurrent urinary retention or suspected detrusor underactivity requiring urodynamic clarification.\n* Post-void residual urine volume more than 250 mL.\n* Uncontrolled coagulopathy.\n* Anticoagulation or antiplatelet therapy that cannot be safely managed perioperatively.\n* Unfitness for anesthesia or intervention.\n* Inability or unwillingness to comply with follow-up.",{"count":486,"type":21},120,[54],"This prospective comparative study will evaluate Water Vapor Thermal Therapy (WVTT\u002FRezum) versus Ejaculation-Sparing Bipolar Transurethral Enucleation of the Prostate (ES-B-TUEP) in sexually active men with symptomatic benign prostatic hyperplasia.\n\nEligible patients will have moderate-to-severe lower urinary tract symptoms, preserved antegrade ejaculation at baseline, and will be candidates for procedural treatment after failure, intolerance, or unwillingness to continue medical therapy. This is not a randomized study. Treatment selection will be based on shared decision-making between the patient and the treating surgeon after standardized counseling about both procedures.\n\nThe study will compare ejaculatory function, urinary symptom improvement, urinary flow, post-void residual urine, erectile function, perioperative outcomes, complications, catheterization duration, hospital stay, medication restart, and retreatment or reintervention during follow-up. The primary outcome will be the change in the Male Sexual Health Questionnaire-Ejaculatory Dysfunction Short Form Function domain score from baseline to 12 months.",[26,27,490],"Ejaculatory Dysfunction",[492,493,494],"Water Vapor Thermal Therapy","Ejaculation-Sparing","MSHQ-EjD-SF","2026-06-10",{"date":423,"type":34},{"date":452,"type":34},{"date":454,"type":21},{"name":456,"class":41},{"id":501,"slug":502,"hasResults":12,"nctId":503,"briefTitle":504,"officialTitle":505,"acronym":4,"eligibilityCriteria":506,"healthyVolunteers":12,"sex":17,"minAge":105,"maxAge":4,"enrollmentInfo":507,"targetDuration":4,"studyType":52,"phases":508,"briefSummary":509,"conditions":510,"keywords":511,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":515,"startDateStruct":516,"completionDateStruct":517,"leadSponsor":518,"locationsCount":97},"100641924","water-vapor-thermal-therapy-versus-ejaculation-preserving-holep-for-benign-prostatic-hyperplasia-100641924","NCT07648875","Water Vapor Thermal Therapy Versus Ejaculation-Preserving HoLEP for Benign Prostatic Hyperplasia","Water Vapor Thermal Therapy Versus Ejaculation-Preserving Holmium Laser Enucleation of the Prostate for Benign Prostatic Hyperplasia: A Prospective Comparative Study","Inclusion Criteria:\n\n* Male patients aged 50 years or older.\n* Symptomatic benign prostatic hyperplasia with moderate-to-severe lower urinary tract symptoms.\n* International Prostate Symptom Score (IPSS) of 13 or higher.\n* Prostate volume 30 to 80 mL measured by transrectal ultrasound.\n* Maximum urinary flow rate (Qmax) of 15 mL\u002Fs or less with voided volume of at least 150 mL.\n* Post-void residual urine volume of 250 mL or less.\n* Failure, intolerance, or unwillingness to continue medical therapy for benign prostatic hyperplasia.\n* Sexually active within the previous 3 months.\n* Preserved antegrade ejaculation at baseline.\n* Patient wishes to preserve ejaculation.\n* Ability to complete the International Prostate Symptom Score (IPSS), International Index of Erectile Function-5 (IIEF-5), and Male Sexual Health Questionnaire-Ejaculatory Dysfunction-Short Form (MSHQ-EjD-SF).\n* Written informed consent.\n\nExclusion Criteria:\n\n* Suspected or confirmed prostate cancer.\n* Abnormal prostate-specific antigen or digital rectal examination suspicious for malignancy unless prostate cancer has been excluded according to standard clinical practice.\n* Previous prostate surgery.\n* Previous urethral surgery likely to affect instrumentation or study outcomes.\n* Urethral stricture disease.\n* Neurogenic bladder dysfunction.\n* Active urinary tract infection until adequately treated.\n* Bladder stones requiring concomitant surgery.\n* Prostate volume less than 30 mL or more than 80 mL.\n* Baseline anejaculation or severe ejaculatory dysfunction.\n* No sexual activity during the previous 3 months.\n* Chronic indwelling urethral or suprapubic catheter.\n* Suspected detrusor underactivity requiring urodynamic clarification.\n* Post-void residual urine volume more than 250 mL.\n* Uncontrolled coagulopathy.\n* Anticoagulation or antiplatelet therapy that cannot be safely managed perioperatively.\n* Unfitness for anesthesia or intervention.\n* Inability or unwillingness to comply with follow-up.",{"count":486,"type":21},[54],"This prospective comparative study will evaluate Water Vapor Thermal Therapy (Rezum) versus ejaculation-preserving Holmium Laser Enucleation of the Prostate (EP-HoLEP) in sexually active men with symptomatic benign prostatic hyperplasia and prostate volume 30-80 mL.\n\nEligible patients will not be randomized. The treatment option will be selected through shared decision-making between the patient and treating physician after standardized counseling about the expected benefits, risks, recovery, catheter duration, urinary outcomes, durability, and potential effects on ejaculation and sexual function.\n\nThe main objective is to compare the change in ejaculatory function from baseline to 12 months using the Male Sexual Health Questionnaire-Ejaculatory Dysfunction-Short Form (MSHQ-EjD-SF) Function domain. Secondary outcomes will include urinary symptom improvement, quality of life, maximum urinary flow rate, post-void residual urine volume, erectile function, antegrade ejaculation preservation, catheterization duration, hospital stay, complications, restart of benign prostatic hyperplasia medication, and retreatment or reintervention within 12 months.",[26,27],[492,512,513,514],"Rezum","Ejaculation-Preserving HoLEP","Male Sexual Health Questionnaire",{"date":423,"type":34},{"date":452,"type":34},{"date":454,"type":21},{"name":456,"class":41},{"id":520,"slug":521,"hasResults":12,"nctId":522,"briefTitle":523,"officialTitle":524,"acronym":525,"eligibilityCriteria":526,"healthyVolunteers":12,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":527,"targetDuration":4,"studyType":52,"phases":529,"briefSummary":530,"conditions":531,"keywords":532,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":540,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":545,"locationsCount":83},"100581357","a-clinical-study-to-evaluate-the-safety-and-efficacy-of-the-flostent-in-men-with-benign-prostatic-hyperplasia-symptoms-100581357","NCT06849258","A Clinical Study to Evaluate the Safety and Efficacy of the FloStent in Men With Benign Prostatic Hyperplasia Symptoms","A Prospective, Multicenter, Double Blind, Randomized, Clinical Study to Evaluate the Safety and Efficacy of The FloStent in Men Suffering From Benign Prostatic Hyperplasia Symptoms","RAPID-III","Inclusion Criteria:\n\n* Male subjects \\> 45 years of age who have symptomatic BPH\n* International Prostate Symptom Score (IPSS) score \\>13\n* Peak urinary flow rate (Qmax): \\>5 mL\u002Fsec and \\\u003C13 mL\u002Fsec with minimum voided volume of \\>125 mL\n* Post-void residual (PVR) \\\u003C250 mL\n* Prostate volume 25 to 80 mL\n* Prostatic urethral length 20-50 mm\n* Able to complete the study protocol and visits\n\nExclusion Criteria:\n\n* Presence of an artificial urinary sphincter or stent(s) in the urethra or prostate\n* Prior minimally invasive intervention or surgical intervention of the prostate or urethra\n* PSA \\>10 ng\u002FmL\n* Bladder cancer or bladder stones\n* Active urinary tract infection (UTI)\n* Uncontrolled diabetes\n* Part of a vulnerable population (cognitively challenged or are incarcerated)",{"count":528,"type":21},215,[54],"The goal of this study is to determine the safety and effectiveness of the FloStent, a medical device used to treat men with symptoms of Benign Prostatic Hyperplasia, compared to sham (procedure without deployment of the FloStent). All participants will undergo a flexible cystoscopy and those randomized to the treatment arm will receive the FloStent, while those randomized to the sham arm will not receive the FloStent.",[26],[533,534,535,78,536,537,538],"benign prostatic hyperplasia","FloStent","Rivermark Medical","LUTS","Lower urinary tract symptoms","enlarged prostate","2026-06-09",{"date":471,"type":34},{"date":542,"type":34},"2025-02-10",{"date":544,"type":21},"2032-12-31",{"name":535,"class":70},{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":551,"acronym":4,"eligibilityCriteria":552,"healthyVolunteers":180,"sex":17,"minAge":18,"maxAge":553,"enrollmentInfo":554,"targetDuration":4,"studyType":52,"phases":556,"briefSummary":557,"conditions":558,"keywords":560,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":562,"lastUpdatePostDateStruct":563,"startDateStruct":564,"completionDateStruct":566,"leadSponsor":568,"locationsCount":97},"100643473","moses-20-vs-magneto-for-holep---a-randomized-controlled-trial-100643473","NCT07632742","Moses 2.0 vs Magneto for HoLEP - a Randomized Controlled Trial","MOSES 2.0 vs Quanta Magneto 150 Holmium Laser for Holmium Laser Enucleation of the prostate-a Randomized Controlled Trial","Inclusion Criteria:\n\n* Undergoing HoLEP for the treatment of bothersome lower urinary tract symptoms\n* Internet access and a device to complete postoperative questionnaires (smartphone, tablet, laptop or desktop computer)\n\nExclusion Criteria:\n\n* Patients who lack decisional capacity\n* Patients unable to read\u002Fspeak English\n* Patients who are on a blood thinner (anticoagulation medication)\n* Patients who do not have internet access to complete postoperative surveys","100 Years",{"count":555,"type":21},180,[54],"The objective of this study is to compare the Magneto 150 holmium laser to the current MOSES 2.0 technology to see if there is a benefit in decreased hemostasis time intraoperatively.",[559,26],"Enlarged Prostate (BPH)",[338,561],"Holmium laser","2026-06-05",{"date":452,"type":34},{"date":565,"type":21},"2026-06",{"date":567,"type":21},"2028-06",{"name":569,"class":41},"Northwestern University",{"id":571,"slug":572,"hasResults":12,"nctId":573,"briefTitle":574,"officialTitle":575,"acronym":576,"eligibilityCriteria":577,"healthyVolunteers":12,"sex":17,"minAge":105,"maxAge":4,"enrollmentInfo":578,"targetDuration":4,"studyType":52,"phases":580,"briefSummary":581,"conditions":582,"keywords":583,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":588,"startDateStruct":589,"completionDateStruct":591,"leadSponsor":592,"locationsCount":97},"100640142","ejaculation-preserving-versus-standard-bipolar-tuep-for-bph-100640142","NCT07629479","Ejaculation-Preserving Versus Standard Bipolar TUEP for BPH","Bipolar Transurethral Enucleation of the Prostate With Preservation of Ejaculation in Patients With Benign Prostatic Hyperplasia: A Randomized Controlled Trial","EP-BTUEP","Inclusion Criteria:\n\n* Male patients with lower urinary tract symptoms secondary to benign prostatic obstruction after failed medical treatment for at least 3 months.\n* Sexually active patients with a continuous relationship with the same partner.\n* International Prostate Symptom Score of 8 or greater.\n* Transrectal ultrasound-estimated prostate size between 40 and 100 cc.\n* Eligible for bipolar transurethral enucleation of the prostate.\n* Ability to complete the required sexual and urinary function questionnaires.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Preoperative sexual dysfunction.\n* Preoperative ejaculatory dysfunction.\n* Diagnosis or suspicion of prostate cancer.\n* Neurological disorders affecting lower urinary tract or sexual function.\n* Detrusor hypocontractility.\n* Catheter-dependent patients.\n* Patients with bladder stones.\n* Inability or refusal to provide informed consent.",{"count":579,"type":21},60,[54],"This prospective randomized controlled trial will compare ejaculation-preserving bipolar transurethral enucleation of the prostate with standard bipolar transurethral enucleation of the prostate in sexually active men with benign prostatic hyperplasia and lower urinary tract symptoms after failed medical treatment. Participants will be randomly assigned to either ejaculation-preserving B-TUEP or standard B-TUEP. The study will evaluate preservation of ejaculatory function, erectile function, urinary symptom improvement, uroflowmetry outcomes, post-void residual urine, perioperative complications, and need for retreatment during follow-up.",[26,27,329],[584,585,343,586],"Bipolar transurethral enucleation of the prostate","B-TUEP","International Prostate Symptom Score","2026-06-01",{"date":562,"type":34},{"date":590,"type":34},"2025-09-08",{"date":93,"type":21},{"name":456,"class":41},{"id":594,"slug":595,"hasResults":12,"nctId":596,"briefTitle":597,"officialTitle":598,"acronym":4,"eligibilityCriteria":599,"healthyVolunteers":12,"sex":17,"minAge":105,"maxAge":4,"enrollmentInfo":600,"targetDuration":4,"studyType":52,"phases":601,"briefSummary":602,"conditions":603,"keywords":604,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":607,"lastUpdatePostDateStruct":608,"startDateStruct":610,"completionDateStruct":612,"leadSponsor":614,"locationsCount":4},"100638203","comparative-outcomes-of-rezm-versus-echolaser-for-treatment-of-benign-prostatic-hyperplasia-with-enlarged-median-lobe-100638203","NCT07578428","Comparative Outcomes of Rezūm Versus EchoLaser for Treatment of Benign Prostatic Hyperplasia With Enlarged Median Lobe.","Comparative Outcomes of Rezūm (Water Vapor Therapy) Versus EchoLaser (Transperineal Laser Ablation) for Treatment of Benign Prostatic Hyperplasia With Enlarged Median Lobe. A Prospective Randomized Comparative Study.","Inclusion Criteria:\n\nInclusion Criteria:\n\nMale patients aged 50 years or older.\n\nDiagnosis of symptomatic BPH with moderate-to-severe lower urinary tract symptoms, defined as an IPSS ≥ 12.\n\nTotal prostate volume between 30 mL and 80 mL, confirmed via Transrectal Ultrasound (TRUS) or mpMRI.\n\nPresence of an enlarged, obstructing intravesical median lobe visualized via imaging or baseline cystoscopy.\n\nPeak urinary flow rate (Qmax) between 5 and 15 mL\u002Fs with a minimum voided volume of ≥ 125 mL.\n\nExclusion Criteria:\n\nConfirmed or suspected prostate cancer (e.g., PSA \\> 4.0 ng\u002FmL without a subsequent negative prostate biopsy or MRI).\n\nHistory of prior surgical interventions for BPH (e.g., TURP, HOLEP, or other MISTs).\n\nPresence of urethral strictures, bladder neck contracture, or established neurogenic bladder dysfunction.\n\nActive urinary tract infection (UTI) or an episode of acute urinary retention requiring an indwelling catheter at the time of screening.\n\nPrevious pelvic radiation therapy or severe pelvic trauma.\n\nInability to safely pause anticoagulant\u002Fantiplatelet therapy per standard hospital perioperative protocols, if applicable.",{"count":260,"type":21},[54],"This study evaluates and compares two minimally invasive surgical therapies for treating men with benign prostatic hyperplasia (BPH) who specifically have an enlarged median lobe. The two treatments being compared are Rezūm (water vapor thermal therapy) and EchoLaser (transperineal laser ablation). Participants will be randomized into two equal groups to receive either the Rezūm treatment or the EchoLaser treatment. The primary goal of the study is to evaluate the change in urinary symptoms over a 6-month period using the International Prostate Symptom Score (IPSS). The study will also assess how well each treatment improves urine flow, reduces the size of the prostate, preserves sexual function, and minimizes complications.",[26],[605,606],"Rezūm","EchoLaser","2026-05-05",{"date":609,"type":34},"2026-05-11",{"date":611,"type":21},"2026-05-01",{"date":613,"type":21},"2027-05-01",{"name":615,"class":41},"Benha University",{"id":617,"slug":618,"hasResults":12,"nctId":619,"briefTitle":620,"officialTitle":621,"acronym":4,"eligibilityCriteria":622,"healthyVolunteers":180,"sex":17,"minAge":105,"maxAge":81,"enrollmentInfo":623,"targetDuration":4,"studyType":52,"phases":624,"briefSummary":625,"conditions":626,"keywords":628,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":607,"lastUpdatePostDateStruct":630,"startDateStruct":632,"completionDateStruct":633,"leadSponsor":634,"locationsCount":97},"100637217","emsella-for-reducing-tsui-after-holep-100637217","NCT07580404","Emsella for Reducing tSUI After HOLEP","The Utility of Emsella for Reducing Transient Stress Urinary Incontinence (tSUI) Following Holmium Laser Enucleation of the Prostate (HoLEP)","Inclusion Criteria:\n\n* Prostate sizing 80-150g\n* Ability to independently transfer and tolerate all 30min Emsella treatments (e.g. not wheelchair bound, no mobility issues)\n* Baseline M-ISI scores \\\u003C4\n* Same-day catheter removal and discharge\n* Able to read, understand, and complete surveys and questionnaires\n\nExclusion Criteria:\n\n* Catheter dependence\n* Previous BPH procedure\n* Previous pelvic surgeries\n* Pre-existing pelvic floor dysfunction\n* Neurogenic bladder\n* Overactive bladder - e.g. prescribed and taking any oxybutynin or mirabegron\n* Preoperative pad-use for incontinence",{"count":42,"type":21},[54],"This study aims to investigate the effectiveness of the Emsella chair treatments at different timepoints. Before and after the holmium laser enucleation of the prostate (HoLEP).",[26,627,559],"Enlarged Prostate With Lower Urinary Tract Symptoms",[338,629],"Emsella",{"date":631,"type":34},"2026-05-12",{"date":565,"type":21},{"date":567,"type":21},{"name":569,"class":41}]